regulatory
confidence high
sentiment positive
materiality 0.75
BioCardia: FDA confirms CardiAMP HF II trial may support PMA for HFrEF therapy
BioCardia, Inc.
- FDA CBER Q-Sub meeting minutes confirm ongoing CardiAMP HF II trial may support Premarket Approval (PMA) for market clearance.
- PMA is the most rigorous FDA device marketing application; previously FDA typically required two trials for large indications like HFrEF.
- FDA had previously determined CardiAMP Cell Therapy System safe, enabling CMS reimbursement in trial.
- Over 1 million U.S. ischemic HFrEF patients could potentially benefit from CardiAMP Cell Therapy.
- Company plans to complete U.S. trial for PMA and submit for regulatory approval in Japan with a post-marketing study.